The Directorate General of Foreign Trade (DGFT) has recently made amendments related to the export of both active pharmaceutical ingredient (API) and formulation of antimalarial drug hydroxychloroquine (HCQ). The notification dated 18 June 2020 states that the regulatory authority has removed the ban on the export policy of HCQ, API, and its formulations. This amendment has been moved from ‘prohibited’ to ‘free’ with immediate effect.
The DGFT had imposed restrictions on the export of HCQ API and formulations on 25 March 2020.
